RhumbLine Advisers’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-49,352
| Closed | -$8.49M | – | 3047 |
|
|
2021
Q3 | $8.49M | Sell |
49,352
-762
| -2% | -$99.7K | 0.01% | 1052 |
|
|
2021
Q2 | $6.29M | Sell |
50,114
-2,955
| -6% | -$373K | 0.01% | 1297 |
|
|
2021
Q1 | $7.2M | Sell |
53,069
-4,032
| -7% | -$521K | 0.01% | 1200 |
|
|
2020
Q4 | $7.31M | Sell |
57,101
-779
| -1% | -$91.3K | 0.01% | 1123 |
|
|
2020
Q3 | $6.51M | Buy |
57,880
+1,756
| +3% | +$175K | 0.01% | 1000 |
|
|
2020
Q2 | $5.35M | Sell |
56,124
-14,952
| -21% | -$1.44M | 0.01% | 1174 |
|
|
2020
Q1 | $6.39M | Buy |
71,076
+1,540
| +2% | +$120K | 0.01% | 893 |
|
|
2019
Q4 | $3.69M | Buy |
69,536
+2,300
| +3% | +$105K | 0.01% | 1444 |
|
|
2019
Q3 | $2.66M | Buy |
67,236
+2,186
| +3% | +$94.8K | ﹤0.01% | 1573 |
|
|
2019
Q2 | $2.67M | Buy |
65,050
+5,937
| +10% | +$246K | 0.01% | 1563 |
|
|
2019
Q1 | $2.75M | Buy |
59,113
+5,779
| +11% | +$254K | 0.01% | 1525 |
|
|
2018
Q4 | $2.32M | Buy |
53,334
+16,757
| +46% | +$837K | 0.01% | 1549 |
|
|
2018
Q3 | $2.09M | Sell |
36,577
-1,545
| -4% | -$75.9K | ﹤0.01% | 1632 |
|
|
2018
Q2 | $1.85M | Buy |
38,122
+1,268
| +3% | +$46.2K | ﹤0.01% | 1714 |
|
|
2018
Q1 | $1.44M | Sell |
36,854
-630
| -2% | -$26.8K | ﹤0.01% | 1781 |
|
|
2017
Q4 | $1.59M | Sell |
37,484
-1,048
| -3% | -$39.3K | ﹤0.01% | 1747 |
|
|
2017
Q3 | $1.44M | Buy |
38,532
+1,315
| +4% | +$45.6K | ﹤0.01% | 1799 |
|
|
2017
Q2 | $1.13M | Buy |
37,217
+4,945
| +15% | +$143K | ﹤0.01% | 1888 |
|
|
2017
Q1 | $854K | Buy |
32,272
+1,284
| +4% | +$33.8K | ﹤0.01% | 1999 |
|
|
2016
Q4 | $791K | Buy |
30,988
+3,454
| +13% | +$109K | ﹤0.01% | 1976 |
|
|
2016
Q3 | $996K | Buy |
27,534
+500
| +2% | +$16.6K | ﹤0.01% | 1805 |
|
|
2016
Q2 | $919K | Buy |
27,034
+3,441
| +15% | +$112K | ﹤0.01% | 1836 |
|
|
2016
Q1 | $623K | Buy |
23,593
+2,950
| +14% | +$85.8K | ﹤0.01% | 2064 |
|
|
2015
Q4 | $1.01M | Buy |
20,643
+1,475
| +8% | +$53.1K | ﹤0.01% | 1798 |
|
|
2015
Q3 | $477K | Buy |
19,168
+483
| +3% | +$14.5K | ﹤0.01% | 2254 |
|
|
2015
Q2 | $591K | Buy |
18,685
+3,215
| +21% | +$104K | ﹤0.01% | 2222 |
|
|
2015
Q1 | $589K | Buy |
15,470
+2,700
| +21% | +$107K | ﹤0.01% | 2197 |
|
|
2014
Q4 | $498K | Sell |
12,770
-550
| -4% | -$19.2K | ﹤0.01% | 2283 |
|
|
2014
Q3 | $403K | Sell |
13,320
-500
| -4% | -$14.1K | ﹤0.01% | 2350 |
|
|
2014
Q2 | $469K | Buy |
+13,820
| New | +$462K | ﹤0.01% | 2316 |
|
RhumbLine Advisers's XLRN Position: Q4 2021 in Review
RhumbLine Advisers sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 49,352 shares — an estimated $8.49M sold.
RhumbLine Advisers first reported a position in XLRN in Q2 2014 and held it in 30 quarters. The position peaked at $8.49M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- RhumbLine Advisers reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- RhumbLine Advisers sold 49,352 Acceleron Pharma shares in Q4 2021, an estimated $8.49M.
- RhumbLine Advisers first reported a position in Acceleron Pharma in Q2 2014 and held it in 30 quarters.
- RhumbLine Advisers's Acceleron Pharma position peaked at $8.49M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.